Eurofins CDMO Alphora announced the development and launch of a new AI-powered software for high throughput salt and co-crystal screening – now a core component of all solid-state screening programs. Developed by Eurofins CDMO Alphora, in collaboration with a local university, this cutting-edge machine learning platform provides highly accurate predictions of salt and co-crystal formation for APIs and intermediates.
This breakthrough technology streamlines solid form selection by minimizing trial and error experimentation, shortening development timelines, and lowering screening costs. With a user-friendly interface and advanced predictive models, the tool empowers clients to make smarter, data-driven decisions earlier in the drug substance development process —resulting in faster, more efficient delivery of optimized solid forms.
Eurofins CDMO Alphora’s seasoned Solid-State R&D team guides partners and customers through every stage of salt and co-crystal development—from data interpretation to experimental strategy. Beyond salt and co-crystal work, the team is well positioned to address a full spectrum of solid-state challenges. Through close cross-departmental collaboration with drug product and drug substance development teams, Eurofins CDMO Alphora delivers fully integrated solutions to improve therapeutic bioavailability and manufacturing processing.